Inclusion Criteria:  Adult axSpA patients satisfying the 2009 Assessment of SpondyloArthritis International Society (ASAS) Classification Criteria Currently enrolled in the SPARCC Program with successful completion of standard data collection protocol in the Spondylitis Clinic of UHN-Toronto Western Hospital Have sustained inactive disease or LDA with an ASDAS of <2.1 or BASDAI <4 for at least 6 months On a stable dose of a TNFi (infliximab, etanercept, adalimumab, certolizumab pegol, or golimumab)  Exclusion Criteria:  Adults axSpA patients with active extra-articular manifestations such as inflammatory bowel disease, psoriasis, and/or uveitis Have comorbidities that may preclude clinical assessment (i.e. fibromyalgia or other chronic pain syndromes; chronic inflammatory diseases other than axSpA) Have diagnosed psychiatric or personality disorders Not enrolled in the Spondyloarthritis Research Consortium of Canada (SPARCC) Program